HCM
CLDX icon

Highbridge Capital Management’s Celldex Therapeutics CLDX Stock Holding History

Highbridge Capital Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-833
Closed -$228K – 1407
2014
Q4 		$228K Sell
833
-9,774
-92% -$2.43M ﹤0.01% 1035
2014
Q3 		$2.06M Buy
10,607
+2,847
+37% +$620K 0.03% 476
2014
Q2 		$1.9M Buy
+7,760
New +$1.75M 0.02% 431
2014
Q1 		– Sell
-1,207
Closed -$438K – 1068
2013
Q4 		$438K Buy
+1,207
New +$465K 0.01% 708

Other funds holding CLDX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
KE
KLP Enterprises Branford, Connecticut $1.97M AUM
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Highbridge Capital Management's CLDX Position: Q2 2017 in Review

Highbridge Capital Management sold out of Celldex Therapeutics (CLDX) in Q2 2017, closing a stake of 10,474 shares — an estimated $567K sold.

Highbridge Capital Management first reported a position in CLDX in Q2 2013 and held it in 8 quarters. The position peaked at $963K in Q1 2014. 130 funds tracked by Wall St. Rank hold CLDX as of Q2 2017.

  • Highbridge Capital Management reported no remaining Celldex Therapeutics position as of Q2 2017 after selling out during the quarter.
  • Highbridge Capital Management sold 10,474 Celldex Therapeutics shares in Q2 2017, an estimated $567K.
  • Highbridge Capital Management first reported a position in Celldex Therapeutics in Q2 2013 and held it in 8 quarters.
  • Highbridge Capital Management's Celldex Therapeutics position peaked at $963K in Q1 2014.
  • 130 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2017.

Based on Highbridge Capital Management's 13F filing for Q2 2017, filed 14 Aug 2017.